Company Introduction

Japan Medical Device Corporation

Member

Member

CHIBA Shuichi

President and CEO / CTO

  • Introduction

    Born in Kobe (city in Japan).

    After joining Fujitsu Kobe Engineering Limited in 1992, worked on software development of telecommunication processors.

    Joined Fujitsu Limited in 2003, worked on research and development of transaction control for mission critical online system, then compiler as a team leader of software development for supercomputer “Kei”. By leading research and development based on a wide range of skills covering low layer to upper-level applications, contributed to development of banking system for Mizuho bank, and supercomputer system for JAXA.

    Participated in Flagship 2020 project since 2007 to lead development of programming environment (compiler, library, etc.) as a development manager of software for the supercomputer “Fugaku”.

    In terms of research and development for “Fugaku”, published a paper on high-speed technology for simulation before completion of “Fugaku”, was awarded “FIT 2018 Funai best paper prize”.

    In November 2020, the supercomputer, “Fugaku” equipped with the developed technology, became the world’s No.1 in four sections 2 years in a row.

    Role

    Management of technology strategy and technology development for practical application and commercialization of digital medical devices utilizing heart simulator technology.

    Creating the way of digital medical care for future medical fields, designing social infrastructure for the new normal era such as connecting with IoT technology.

    In addition to technology research centered on the supercomputer “Fugaku”, fostering engineers with consideration of post “Fugaku” and contributing to the future society benefited by supercomputers.

    Thoughts on heart simulator

    When I was considering how to expand my expertise of supercomputer technology to social issues, I decided to participate in the medical field as a trigger of my father’s death due to cardiovascular diseases.

    I would like to help as many patients and medical professionals as possible by practicalizing digital medicine utilizing heart simulator technology.

OKANO Takafumi

COO

  • Career

    Entered Dept of Science I, The University of Tokyo in 1997.

    Received Master’s degree from Department of Quantum Engineering and Systems Science, the University of Tokyo in 2003.

    Joined Fujitsu Limited in 2003, Consulting division (2003~),
    Group management division (2007~), New business planning division (2017~), Healthcare division (2020).

    Acting executive officer, PIA Co., Ltd. in Jan 2019, seconded to PIA in Jul 2020.

    Thoughts on heart simulator

    Japan Medical Device Corporation was established on November 16th, 2020, independently by PIA Co., Ltd for “First class medical devices marketing license”. We are working on developing the business of new medical devices based on medical device marketing know-how cultivated in PIA, as well as the leading-edge technology of the heart simulator. The heart simulator was developed on a supercomputer by the University of Tokyo and Fujitsu Limited over a period of more than 10 years. Both advanced modeling technology covering the organ level to the molecule level, and ultra high-speed computing technology have made it possible to reproduce human organs in the virtual space. With this technology, we plan to develop and provide several medical services as follows:
    ● Replace invasive medical inspection procedures for patients
    ● Support doctors to decide method of difficult operations
    ● Predict the effect of treatment after the operation
    ● Recognize the condition of small blood vessels
    We will expand our business aiming for worldwide improvement of the quality of life for humans.

    This business consists of three organizations as key players: the University of Tokyo, Fujitsu and PIA. I believe my mission is to provide the heart simulator as excellent technology for the world by linking these three organizations. I feel confident in my mission as I have belonged to these three organizations (refer to my career description below). I commit my life to achieving the purpose of this business. In addition, strong minded and trusted colleagues have gathered. Please refer to their introductions.

    This business is based on great social significance. Your heart will be virtually reproduced prior to the diagnosis and treatment for you to understand your heart condition, and the effect of the treatment will be predicted. We would like to create an unprecedented digital medical world as mentioned above.

SATO Hiroshi

CFO

  • Introduction

    After graduating from the Faculty of Law at Waseda University, he was involved in the VC investment business at Japan Asia Investment Co., Ltd., and was stationed in Japan and three other Asian countries.

    After participating in the management of a venture company and serving as the CEO of a local subsidiary in the United States, he was in charge of all management operations as a Board Member and Administration Director at GungHo Gamania Co., Ltd. (Hong Kong), a subsidiary of GungHo Online Entertainment, Inc.

    Thoughts on heart simulator

    I am very excited to be able to participate in a business based on heart simulation. When I look around, I notice that there are many people with heart problems.

    I have several relatives who have suffered myocardial infarction, and my younger cousin, who has already passed away, was also battling congenital heart disease.

    In the world of medical care, which continues to evolve day by day, I will develop this heart simulation-based business with aspiring colleagues so that many people suffering from such difficult heart diseases can maintain a healthy life or regain their health.

Simon Downes

Representative
in the USA

  • Introduction

    Lived in the UK, and California, and worked for Kaiser Permanente Emergency Department in San Francisco (1989-1992) before departing for Japan.

    Arrived in Japan in 1992, studied Japanese while teaching English, and completed a doctorate in developmental psychology at the University of Tsukuba (1997-2002), followed by a post-doctorate in clinical psychology (2002-2005).

    As a trained clinical psychologist operated a bilingual preschool (2003-2010),and served as a staff counselor at the University of Tsukuba in Tokyo (2013-2018).

    Professor at Rikkyo University (Tokyo campus) Department of Law & Politics (2011-2019).

    Entered medical school in Japan, and traveled to the United States to complete clinical rotations in Chicago, Illinois, and Mcallen, Texas (2019-2021) which included two clinical clerkships in cardiology, the most recent at McAllen Heart Hospital.

    This coincided with the launching of JMD.

    Medical article editor for 25 years in Japan, and published own journal articles on subjects ranging from psychology, bilingual education, and neurosurgery.

    Now residing in New York City, completing medical licensing exams.

    Expertise

    ● Academic medical writing

    ● Research and strategy for regulatory marketing and correspondence

    ● Medical video editing, digital and social media, webpage design

    Role

    United States representative for JMD, and regulatory affairs team member for the FDA, UK, and EU markets.

    Thoughts on heart simulator

    During my cardiology rotations, I observed various invasive heart procedures and participated in the placement of CRT pacemakers.

    This experience showed me how critical decision-making directly affects the success of cardiac resynchronization therapy.

    The innovative technology of the heart simulator will have a significant influence on cardiology diagnoses and treatment for patients of all ages.

TOKUMARU Yoshihiko

Director
Business Operation Division

  • Introduction

    Graduated from School of Political Science and Economics, Waseda University in 1978 and joined Fujitsu Limited.

    After working as a systems engineer in Japan, worked in United States (1988-1994) and Australia (1998-2004), returned to the consulting business division.

    After serving as a Deputy Director, moved to Fujitsu Research Institute in 2007 due to consolidation of the Fujitsu Group’s consulting business and served as head of a consulting group and economics research group as the executive managing director.

    Returned to Fujitsu Limited as executive strategist in 2017.

    Joined JMD in 2021.

    Expertise

    ● Planning, developing, and executing consulting services for the white-collar productivity improvement

    ● Planning and executing “Field Innovation”, practice and fostering “Field Innovators”.

    ● Developing, executing, and disseminating Japanese version of “Results Chain”, a consensus development method to integrate business, people and IT.

    ● Planning and executing “Digital Innovation” practice and fostering “Digital Innovators”.

    ● Managing social science laboratory

    ● Consulting and lecturing for above mentioned fields

    Thoughts on heart simulator

    I believe it is necessary to maintain and increase sustainable business capability to contribute to society with a firm identity as a corporation. We would like to provide as many people as possible with the benefits of the leading-edge functions of the heart simulator, through the business model called “MDaaS (Medical Device as a Service)” which supplies advanced and complex medical simulation as a service. To complete this mission, it is necessary to create an unprecedented business scheme and process.

    I will devote myself to manage the business operations of JMD to make contributions to society such as patient QOL improvement, medical risk mitigation and medical cost reduction with the best of all my knowledge and experience in various industries.

MINAMI Kazuo,PhD

Director
R&D Division

  • Introduction

    In 1981, graduated from Department of Physics (major in particle physics and quantum mechanics), College of Science and Technology, Nihon University. Joined Fujitsu Limited as a systems engineer and worked on optimization of simulation code and development of business systems.

    In 2000, left Fujitsu Limited as a manager, joined RIST (Research organization for Information Science and Technology), worked on development of application for geophysical sciences and nano technology field on the Earth Simulator.

    Since 2008, worked on development of application for “KEI” as an application development team leader of “KEI” development project at the Institute of Physical and Chemical Research.

    In 2013, left RIST, formally joined the Institute of Physical and Chemical Research. Since then, worked on operating “KEI” as head of software technical team and unit leader of application tuning development at the Center for Computational Science.

    Since 2014, worked on development of application for “FUGAKU” in the 2020 flagship project.

    In 2017, completed the doctoral program at School of Systems and Informatics of Kobe University, obtained a Doctor of Engineering degree. The doctoral dissertation theme is “Research on application execution performance optimization technology”.

    Awards and Research results

    ● In 2011, Gordon Bell Award, Association for Computing Machinery 2014-2017, 1st and 2nd place at HPCG Benchmark

    ● In 2017, jointly published “The Art of High Performance Computing for Computational Science, Vol. 2” (Japanese version, Osaka University Press, Editor-in chief: Masaaki Geshi, coauthor for chapters 1-3).

    ● In 2019, jointly published “The Art of High Performance Computing for Computational Science, Vol. 2 (English version, Springer, Singapore, Editor-in chief: Masaaki Geshi, coauthor for chapters 1-3).

    Expertise

    Based on background of physics, specializes in performance measurement, performance evaluation, app characteristic analysis, high parallelization, performance optimization, etc. by interpreting application codes running on computers representing a supercomputer.

    Experienced in developing peripheral systems of application.

    Thoughts on heart simulator

    The use of simulation in the industrial field is progressing, but the application of simulation technology to the medical field is under development.

    I would like to be deeply involved in establishing it as medical business in the medical field by utilizing simulation technology built up through my experience.

    By doing so, I would like to achieve a contribution to society.

SHIMO Jinse

Director
Service Design Division

  • Career

    In Mar. 2011, graduated from Department of Electronics and Information Engineering, National Institute of Technology, Fukui.

    In Mar. 2015, received master’s degree from Department of Electronic and Information Science, Graduate School of Natural Sciences, Kanazawa University.

    In Apr. Joined Fujitsu Limited.

    Introduction

    After joining Fujitsu, worked as a systems engineer in the common technology department, developing IoT applications through Agile and developing cloud-based web applications.

    After moving to a new business division, utilized Agile know-how and development skills to participate in a new business creation project that made full use of digital technology for customers, such as music, automobiles, and transportation and was consistently involved in concept design, UX design, and verification through a cross-domain approach to business design based on engineering skills.

    Based on these experiences, I found value in promoting business as a business entity rather than supporting customers’ creation of new businesses, and together with Mr. Okano, I have been working on developing the business of the heart simulator.

    When JMD which develops the business of the heart simulator was established, I immediately decided to join JMD as a launch member without thinking to return to my previous job.

    Thoughts on heart simulator

    I believe it is necessary to develop human centric services, products and systems in order for high-end technologies such as the heart simulator to blend into the world.

    Focusing not only on patients, but also on doctors, healthcare professionals, simulation operators, and many other stakeholders, I will create services, products, and systems that are close to everyone.

    In addition, I have had the painful experience of my father’s death from cancer a few years ago, and I have a strong desire to be useful in the medical field as an engineer.

    I promise to complete this work and deliver the world’s best technology heart simulator to as many patients as possible.

Researchers
SHIRAISHI Isao

Senior Scientist
Emeritus Visiting Scientist,National Cerebral and Cardiovascular Center

Visit “ped UT-Heart Lab” to learn more 〉

Company Profile

Company Profile

Trade name Japan Medical Device Corporation
Founded 2020.11.16
Capital 313.5 million yen (as of 2023.11.1)
Location 【Head office】
Kawasakinisshincho Building
7-1, Nisshincho, Kawasaki-ku
Kawasaki-shi, Kanagawa
210-0024, Japan
【Kobe office】
Kobe Hybrid Businness Center(KHBC)
6-7-6, Minatojima Minamimachi, Chuo Ward
Kobe, Hyogo
650-0047, Japan
【ped UT-Heart Laboratory & Computer Center】
Open Innobation Lab (OIL)
National Cerebral and Cardiovascular Center
6-1, Kishibeshinmachi
Suita, Osaka
564-8565, Japan
Representative CHIBA Shuichi (President and CEO/CTO)
OKANO Takafumi (COO)
SATO Hiroshi (CFO)
MIYATA Kazuo (Audit & Supervisory Board Member)
Advisors HISADA Toshiaki (PhD, Professor Emeritus, the University of Tokyo)
SUGIURA Seiryo (MD, Professor Emeritus, the University of Tokyo)
Employees 15 (as of 2024.7.1)
Business description Research and development of new medical computer simulation services utilizing heart simulator called “UT-Heart®”
Licenses First Class Medical Devices Marketing License (14B1X10036)
Medical Devices Manufacturing License (14BZ200408)

Founding Story

Founding Story

The heart simulator is the world’s best technology developed by the University of Tokyo and Fujitsu Limited over more than 10 years with a supercomputer.

The movement of an individual heart is reproduced accurately from micro to macro level through input of imaging data such as CT and ultrasound together with clinical data.

We are developing a new programmed medical device utilizing this simulation technology.

Visit “Heart Simulator” to learn more 〉

To bring this device to the world, it is necessary to ensure quality and safety. This requires pharmaceutical approval in Japan, FDA 510(k) in the U.S., and CE mark in Europe.

The application know-how of the company authorized for manufacturing and distribution of medical device who is responsible for quality and safety is essential.

Therefore, PIA Co., Ltd., which has a business license for “First class medical devices marketing” which handles advanced medical equipment, has been added as a business partner. As a proof of this, on April 23, 2020, we signed a joint research agreement with UT-Heart Research Institute Co., Ltd. (a venture from the University of Tokyo), Fujitsu, and PIA.

Visit Movie to learn the contract details  〉

Japan Medical Device Corporation was founded on 16th November, 2020 independently by PIA. JMD will take over PIA’s manufacturing and distribution know-how for the business of the heart simulator developed by the University of Tokyo and Fujitsu to target the world. One of our goals is to be listed on NASDAQ in the future.

Visit Information from us 〉

Business Collaboration Partners

Business Collaboration Partners

Research institutes
Hospitals /
Universities